Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
14.12
Nov 05 • 3:59 PM ET Dollar change-0.70 Percentage change(-4.72%)
Aftermarket Close
14.12
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.10B
Enterprise Value
2.79B
Income
13.01M
Sales
1.66B
Book/sh
13.71
Cash/sh
4.01
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4427
IPO
Aug 16, 1995
P/E
85.84
Forward P/E
5.96
PEG
1.72
P/S
0.66
P/B
1.03
P/C
3.52
P/FCF
12.81
EV/EBITDA
8.05
EV/Sales
1.68
Quick Ratio
2.21
Current Ratio
3.62
Debt/Eq
1.88
LT Debt/Eq
1.82
Option/Short
Yes / Yes
EPS (ttm)
0.16
EPS next Y
2.37
EPS next Q
0.64
EPS this Y
4.71%
EPS next Y
1.49%
EPS next 5Y
3.46%
EPS past 3/5Y
- -
Sales past 3/5Y
1.63% 3.57%
EPS Y/Y TTM
102.60%
Sales Y/Y TTM
0.84%
EPS Q/Q
368.47%
Sales Q/Q
2.27%
Insider Own
14.48%
Insider Trans
0.00%
Inst Own
95.55%
Inst Trans
-0.65%
ROA
0.36%
ROE
1.24%
ROIC
0.43%
Gross Margin
54.85%
Oper. Margin
11.63%
Profit Margin
0.79%
SMA20
7.73%
SMA50
-3.40%
SMA200
0.14%
Trades
Shs Outstand
77.81M
Shs Float
66.54M
52W High
20.49 -31.09%
52W Low
8.70 62.30%
Volatility
7.07% 5.76%
ATR (14)
0.83
RSI (14)
53.77
Beta
1.29
Rel Volume
1.02
Avg Volume
971.76K
Volume
991,991
Perf Week
10.05%
Perf Month
8.62%
Perf Quarter
-18.14%
Perf Half Y
4.13%
Perf YTD
13.69%
Perf Year
23.86%
Perf 3Y
-63.56%
Perf 5Y
-80.45%
Perf 10Y
-63.09%
Prev Close
14.82
Price
14.12
Change %
-4.72%
Consensus
Hold
Avg. Price Target
$15.67
Implied Upside
+11.0%
Analysts11incl. previous ratings
Rating Distribution3 Buy · 6 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 28, 2026Initiated
UBS logoUUBS
Neutral$19+34.6%
Jul 09, 2026Initiated
BMO logoBBMO Capital Markets
Market Perform$19+34.6%
Jun 18, 2026Upgrade
AArgus
Hold → Buy$25+77.1%
May 28, 2026Upgrade
C logoCCitigroup
Sell → Neutral$16+13.3%
Apr 15, 2026Downgrade
AArgus
Buy → Hold
Mar 31, 2025Upgrade
AArgus
Hold → Buy
Dec 02, 2024Initiated
MS logoMMorgan Stanley
Underweight$25 → $20+41.6%
Oct 07, 2024Upgrade
BBTIG Research
Sell → Neutral
Jul 30, 2024Downgrade
C logoCCitigroup
Neutral → Sell$30 → $23+62.9%
Jul 30, 2024Downgrade
BBTIG Research
Neutral → Sell$22+55.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '26Option Exercise0.0018,922040,612Mar 12 06:10 PM
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '26Option Exercise0.001,216023,152Mar 12 06:10 PM
Poul MojdehPresident & CEOJan 06 '26Option Exercise0.001,39001,390Jan 07 04:10 PM
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
CEODr. Stuart M. Essig Ph.D.
Executive VP & CFOMs. Lea Daniels Knight
Executive Vice President of Tissue Reconstruction and Distributed TechnologiesMr. Robert T. Davis Jr.
Executive VP & Chief Commercial OfficerMr. Michael J. McBreen
Executive VP & President of International BusinessMr. Harvinder Pal Singh